Vision Loss After GLP-1 Weight-Loss Drugs

Including NAION and optic nerve damage diagnosed after Ozempic, Wegovy, or Mounjaro use.

Have You Been Diagnosed With Vision Loss After a GLP-1 Drug?

You may qualify for compensation.
Only medically diagnosed or treated cases accepted.
↓ ↓ ↓

Quick Facts: GLP-1 Drugs and Diagnosed Vision Loss

GLP-1 receptor agonists are commonly prescribed for diabetes and weight loss.
Recent medical research has raised concerns about a potential link between GLP-1 drugs and serious vision injuries, including NAION and optic nerve damage, in some patients.

  • Drug Class: GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro, semaglutide)
  • Common Uses: Type 2 diabetes and weight management
  • Vision Risk: Reported cases of NAION and optic nerve injury following GLP-1 use. Read research
  • Reported Symptoms: Sudden vision loss, partial blindness, blurred or dim vision

Free GLP-1 Vision Loss Case Review

CALL NOW:  1-866-374-0338

Have you or your loved one experienced either of the following after using a GLP-1 medication?(Select all that apply)

Have you or your loved one experienced either of the following?
(Select all that apply)
Have you or your loved one experienced either of the following?
(Select all that apply)
I acknowledge that by submitting this form, I am agreeing to the Terms of Use and Privacy Policy of The Johnson Law Firm. I understand that submission of this form does not create an attorney-client relationship, and that any information I provide will be used to evaluate my potential case. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Do You Qualify for a GLP-1 Vision Loss Case Review?

Medical Criteria

Most eligible claimants meet one or more of the following:

  • Took a GLP-1 receptor agonist, including semaglutide (Ozempic®, Wegovy®) or tirzepatide (Mounjaro®, Zepbound®)
  • Diagnosed with NAION, optic neuropathy, or optic nerve damage
  • Experienced sudden or permanent vision loss
  • Symptoms began during or shortly after GLP-1 use
  • No prior eye condition that fully explains the vision loss
  • Willing to provide medical and prescription records

Preferred Documentation

If you don’t yet have these, our team can help you secure them

  • Prescription records showing GLP-1 drug use
  • Diagnosis or notes from an ophthalmologist or neurologist
  • Optic nerve or retinal imaging (OCT, visual field testing)
  • Timeline noting when vision symptoms began
  • Emergency room visits or hospitalization records related to vision
  • Emergency or hospital records related to vision loss (if applicable)

If you have been medically diagnosed with vision loss or NAION after GLP-1 use, we offer a free case review.
Get a free Ozempic vision loss lawsuit case review →

Symptoms Reported in Diagnosed GLP-1 Vision Loss Cases

Patients who were later diagnosed with vision loss or NAION after using GLP-1 medications have reported symptoms such as the following.

Respiratory depression
Sudden vision loss in one eye
Loss of conciousness
Blurred or cloudy vision
Severe Sedation
Dark spots or shadows in vision
Confusion or disorientation
Loss of peripheral vision
Nausea or vomiting
Color vision problems
Skin irritation or burns
Light sensitivity (photophobia)
Diagnosed With Vision Loss? Request Review →

ALERT: Act quickly – many patients don’t realize their vision problems may be linked to GLP-1 drugs like Ozempic until it’s too late.

What Is NAION (Nonarteritic Anterior Ischemic Optic Neuropathy)?

NAION is a serious eye condition that occurs when blood flow to the optic nerve is reduced, causing sudden vision loss – often in one eye.
It is considered a medical emergency and is typically diagnosed by an ophthalmologist or neurologist through clinical examination and imaging.

Common features of NAION include:

  • Sudden, painless vision loss (often upon waking)
  • Blurred or dim vision
  • Loss of peripheral or central vision
  • Optic nerve swelling or damage

Recent medical research has raised concerns about a possible association between GLP-1 receptor agonists (such as semaglutide and tirzepatide) and an increased risk of NAION in certain patients.
If you have been medically diagnosed with NAION after using a GLP-1 medication, you may qualify for a legal case review.

GLP-1 Vision Loss Litigation Timeline

Federal litigation involving GLP-1 medications is evolving as courts evaluate claims related to diagnosed vision loss, including NAION and optic nerve damage. Below is a high-level timeline of notable procedural developments.

Jul 2024

July 2024 – Harvard Study Links Semaglutide to NAION Risk

A pivotal study published in JAMA Ophthalmology identified a statistically significant association between the GLP-1 medication semaglutide (Ozempic, Wegovy) and Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) – a condition that can cause sudden, irreversible vision loss. This study marked the first peer-reviewed evidence suggesting GLP-1 drugs may contribute to optic nerve damage. Read the Harvard-led JAMA Ophthalmology Study
DEC 2024

DECEMBER 2024 – Danish Study Finds 2X Higher NAION Risk with GLP-1 Drugs

A large population-based study published in the International Journal of Retina and Vitreous found that once-weekly semaglutide users had more than twice the five-year risk of developing NAION compared to non-users. The results bolstered vision loss lawsuits, providing robust statistical evidence of a drug-related optic nerve risk.
FEB 2025

FEBRUARY 2025 – Major U.S. Study Confirms GLP-1 Vision Loss Link

A February 2025 study in JAMA Ophthalmology confirmed an increased risk of NAION in GLP-1 users across multiple large healthcare databases. This marked the most comprehensive U.S.-based data yet tying semaglutide and liraglutide to irreversible blindness from optic nerve damage, further strengthening legal claims.
DEC 2025

DECEMBER 2025 – Vision Loss Lawsuits Centralized in MDL 3163

On December 15, 2025, the U.S. Judicial Panel on Multidistrict Litigation created MDL No. 3163, centralizing all federal lawsuits involving GLP-1 drug–related NAION claims. The cases, involving drugs like Ozempic, Wegovy, Trulicity, and Mounjaro, were assigned to Judge Karen S. Marston in the Eastern District of Pennsylvania. This new MDL marks a major turning point for plaintiffs alleging blindness and optic nerve damage from GLP-1 medications.

Diagnosed With Vision Loss
After a GLP-1 Drug?

Get answers. Get help. Start your free vision loss case review today.

Call Now!
1-866-374-0338

or

Get Started!
Request a callback online

With over 30 years of experience and more than $100 million recovered, The Johnson Law Firm has stood up to major drug manufacturers and won. We’re proud to represent clients across the U.S. in high-stakes litigation involving defective medications.

Real Results From Real Clients

“I was scared before I hired The Johnson Law Firm. They fought for me – and I was overwhelmed with the result. I received half a million dollars.”
— Nina S.

GLP-1 vision loss lawsuit client consultation

How a GLP-1 Vision Loss Case Is Evaluated

Federal courts are currently evaluating claims involving GLP-1 medications and medically diagnosed vision injuries, including NAION and optic nerve damage.
Below is an overview of how these cases are typically reviewed and evaluated when a confirmed diagnosis is present.

  • Medical Evaluation: Cases begin with a review of medical records confirming vision loss, NAION, or optic nerve injury, typically diagnosed by an ophthalmologist or neurologist.
  • Case Consolidation: Certain federal cases involving GLP-1 medications have been centralized to streamline pretrial proceedings, expert review, and discovery.
  • Causation Proof: Medical experts – including ophthalmologists and neurologists—testify about the connection between GLP-1 receptor agonists and optic neuropathy or NAION (a serious, irreversible eye condition).
  • Core Legal Allegations:
  • Failure to Warn: Drugmakers failed to alert users about potential vision risks.
  • Negligent Marketing: Risks may have been downplayed or omitted in consumer materials.
  • Defective Design: Some claims allege the drug’s mechanism could trigger vision damage in susceptible patients.
  • Compensation: If successful, plaintiffs may be entitled to financial compensation covering a range of damages. This includes medical costs related to eye treatments or surgeries, loss of income due to vision impairment, pain and suffering, emotional distress, and any permanent loss of vision that impacts daily life or earning ability.
  • Settlement vs. Trial: Most lawsuits in MDLs result in confidential settlements. However, bellwether trials beginning in 2025 may set precedent and shape payouts.
  • Contingency-Fee Promise: Our firm handles these cases on a contingency-fee basis – you pay nothing unless we win compensation for you.

Results-Driven Representation: Our team will marshal the latest science, review your medical records at no cost, and fight for the maximum compensation you deserve.

Our GLP-1 Vision Loss Case Review Process

At The Johnson Law Firm, we focus on careful evaluation of medically documented vision injuries allegedly associated with GLP-1 medications. Our role is to review medical records, consult with qualified experts, and determine whether a claim may warrant further legal action.

Here’s how the process works:

  • Free Case Evaluation: We’ll review your medical history, pharmacy records, and vision-related symptoms — at no cost — to determine if you may qualify for an Ozempic vision loss claim.
  • Medical Expert Support: Our legal team collaborates with ophthalmologists, neurologists, and GLP-1 research experts to evaluate evidence of optic nerve damage or sudden blindness linked to these medications.
  • Regulatory & Scientific Review: We examine FDA safety data, adverse event reports, and recent clinical research (including Harvard’s NAION study) to build a strong foundation for your case.
  • MDL Participation: If your case is eligible, we’ll consider filing it in file it in either MDL No. 3094, the federal multidistrict litigation centralized in the Eastern District of Pennsylvania or another appropriate court – streamlining the legal process and improving your chances of meaningful compensation.
  • No Fees Unless We Win: We work on a contingency-fee basis – you pay nothing unless we successfully recover money for your medical bills, vision-related losses, and suffering.

Results-Driven Representation: Focus on your health while we fight for maximum recovery.

GLP-1 Vision Loss FAQs

You may be eligible if you took Ozempic, Wegovy, Zepbound, or Mounjaro and later experienced vision loss, optic nerve damage (such as NAION), blurry vision, or blindness – especially if symptoms began during or shortly after use.

Claims under review generally involve allegations that certain GLP-1 medications may be associated with reported vision injuries, including NAION and optic nerve damage, and that risks may not have been fully disclosed.
Each case is evaluated individually based on medical records, timing of drug use, and expert review. No outcomes are guaranteed.

Yes. A 2024 Harvard-led study published in JAMA Ophthalmology found that users of semaglutide were up to 8 times more likely to develop NAION, a leading cause of sudden blindness. This research is central to current legal claims.

Multidistrict Litigation (MDL) No. 3094 consolidates all federal lawsuits involving GLP-1 drugs into one court in the Eastern District of Pennsylvania, streamlining the process for discovery, motions, and bellwether trials.

Compensation may include payment for medical costs, lost wages, loss of future earnings, vision-related disability, emotional distress, and pain and suffering. Some cases may also seek punitive damages.

There are no upfront costs. Our firm works on a contingency-fee basis – you pay nothing unless we recover money for you.

Deadlines vary by state, but time is limited. If you suspect your vision loss is connected to a GLP-1 drug, it’s important to act quickly to preserve your rights and evidence.

Request a GLP-1 Vision Loss Case Review

Our legal team reviews cases involving medically diagnosed vision loss, including NAION or optic nerve damage, reported after use of GLP-1 medications such as semaglutide or tirzepatide.

I acknowledge that by submitting this form, I am agreeing to the Terms of Use and Privacy Policy of The Johnson Law Firm. I understand that submission of this form does not create an attorney-client relationship, and that any information I provide will be used to evaluate my potential case. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trusted nationwide. Thousands of clients. Millions recovered. No fees unless we win.

Ribbon Award Icon

35+ Years of Experience

Since 1993, trusted nationwide
Ribbon Award Icon

$100M+ Recovered to Clients

Product liability & mass torts
Ribbon Award Icon

No Fees Unless We Win

You pay nothing upfront
Ribbon Award Icon

Nationwide Representation

Clients in all 50 states